At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 target
Drug / intervention
RITUXIMABdrug
Likely dose
RITUXIMAB 375 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Burkimab:Study Multicenter of Optimization of the Treatment of LLA-B and the Burkitt's Lymphoma in Adult Patients (From 15 Years Old)
In Brief
A Phase 2 clinical trial evaluating RITUXIMAB for Acute Lymphoblastic Leukemia and Burkitt's Lymphoma. Completed, enrolled 20 participants across 15 sites.
Detailed Summary
The purpose of this clinical trial is to prove the efficacy of the following new regimen treatment: * Administration of anti-CD20 (Rituximab) combined with chemotherapy. * Combined treatment with high doses of methotrexate and high doses of cytarabine with conventional cytostatics (block C) * Prophylactic administration of G-CSF after all chemotherapy cycles * local irradiation after 6 cycle if CNS was affected or if there are residual tumour
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Lymphoblastic Leukemia, Burkitt's Lymphoma
CountriesSpain
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2006
First PostedOct 2006
Primary CompletionDec 2013
TodayJul 2026
First PostedOct 16, 2006
Enrollment StartAug 1, 2006
Primary CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 7.3 yearsPosted 19.7 years ago
Interventions
RITUXIMABdrug
375 mg/m2/d day 1